Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 379,500 shares, a growth of 600.2% from the March 31st total of 54,200 shares. Currently, 4.4% of the company’s stock are sold short. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 0.3 days.

Xilio Therapeutics Trading Down 4.7 %

NASDAQ XLO opened at $1.01 on Friday. The firm has a market capitalization of $34.81 million, a P/E ratio of -0.36 and a beta of -0.12. The firm’s fifty day moving average price is $0.91 and its two-hundred day moving average price is $1.03. Xilio Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.40.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.64) earnings per share for the quarter. On average, research analysts anticipate that Xilio Therapeutics will post -1.53 EPS for the current fiscal year.

Insider Buying and Selling at Xilio Therapeutics

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was acquired at an average price of $0.76 per share, with a total value of $368,790.00. Following the completion of the transaction, the insider now owns 7,345,473 shares in the company, valued at $5,582,559.48. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC acquired a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned approximately 0.09% of Xilio Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.